Leonard R Prosnitz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Leonard R Prosnitz has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Anne W. Beaven
A Div. of Hematologic Malignancy and Cellular Therapy , Duke University Medical Center Durham , NC , USA
1 shared publication - Christopher Kelsey
Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina
1 shared publication - Gloria Broadwater
Cancer Statistical Center, Duke Cancer Institute, Durham, NC, USA
1 shared publication - Jennifer A Dorth
Department of Radiation Oncology, University Hospitals Seidman Cancer Center and Case Western Reserve University, 11100 Euclid Avenue, Cleveland, OH 44106, USA
1 shared publication
Latest Publications
- Open Access
- 21 June 2012
- Published by Springer Nature in Radiation Oncology
- Vol. 7 (1) , 100
Radiotherapy dose–response analysis for diffuse large B-cell lymphoma with a complete response to chemotherapy
To examine the efficacy of different radiation doses after achievement of a complete response to chemotherapy in diffuse large B-cell lymphoma (DLBCL). Patients with stage I-IV DLBCL treated from 1995-2009 at Duke Cancer Institute who achieved a complete response to chemotherapy were reviewed. In-field control, event-free survival, and overall survival were calculated using the Kaplan-Meier method. Dose response was evaluated by grouping treated sites by delivered radiation dose. 105 patients were treated with RT to 214 disease sites. Chemotherapy (median 6 cycles) was R-CHOP (65%), CHOP (26%), R-CNOP (2%), or other (7%). Post-chemotherapy imaging was PET/CT (88%), gallium with CT (1%), or CT only (11%). The median RT dose was 30 Gy (range, 12-40 Gy). The median radiation dose was higher for patients with stage I-II disease compared with patients with stage III-IV disease (30 versus 24.5 Gy, p < 0.001). Five-year in-field control, event-free survival, and overall survival for all patients was 94% (95% CI: 89-99%), 84% (95% CI: 77-92%), and 91% (95% CI: 85-97%), respectively. Six patients developed an in-field recurrence at 10 sites, without a clear dose response. In-field failure was higher at sites ≥ 10 cm (14% versus 4%, p = 0.06). In-field control was excellent with a combined modality approach when a complete response was achieved after chemotherapy without a clear radiation dose response.
- 21 June 2012
- Published by Springer Nature in Radiation Oncology
- Vol. 7 (1) , 100
Open AccessRadiotherapy dose–response analysis for diffuse large B-cell lymphoma with a complete response to chemotherapy
To examine the efficacy of different radiation doses after achievement of a complete response to chemotherapy in diffuse large B-cell lymphoma (DLBCL). Patients with stage I-IV DLBCL treated from 1995-2009 at Duke Cancer Institute who achieved a complete response to chemotherapy were reviewed. In-field control, event-free survival, and overall survival were calculated using the Kaplan-Meier method. Dose response was evaluated by grouping treated sites by delivered radiation dose. 105 patients were treated with RT to 214 disease sites. Chemotherapy (median 6 cycles) was R-CHOP (65%), CHOP (26%), R-CNOP (2%), or other (7%). Post-chemotherapy imaging was PET/CT (88%), gallium with CT (1%), or CT only (11%). The median RT dose was 30 Gy (range, 12-40 Gy). The median radiation dose was higher for patients with stage I-II disease compared with patients with stage III-IV disease (30 versus 24.5 Gy, p < 0.001). Five-year in-field control, event-free survival, and overall survival for all patients was 94% (95% CI: 89-99%), 84% (95% CI: 77-92%), and 91% (95% CI: 85-97%), respectively. Six patients developed an in-field recurrence at 10 sites, without a clear dose response. In-field failure was higher at sites ≥ 10 cm (14% versus 4%, p = 0.06). In-field control was excellent with a combined modality approach when a complete response was achieved after chemotherapy without a clear radiation dose response.